Liver transplantation: Current status in British Columbia

British Columbia Medical Journal

Volumn 52, Issue 4, 2010, Pages 203-210

  Haque, Mazhar ^a   Scudamore, Charles H ^a   Steinbrecher, Urs P ^a   Chung, Stephen W ^a   Buczkowski, Andrzej K ^a   Erb, Siegried R ^a   Yoshida, Eric M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77952003891     PISSN: 00070556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Starzl TE, Klintmalm GB, Porter KA, et al. Liver transplantation with use of cyclo-sporin a and prednisone. N Engl J Med 1981;305:266-269.
2. The US Multicenter FK506 Liver Study Group. A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 1994;331:1110-1115.
3. Walker SR, Parsons DA, Coplestons P, et al. The Canadian Organ Replacement Register. Clin Transpl 1996:91-107.
4. Hunt CM, Tart JS, Dowdy E, et al. Effect of orthotopic liver transplantation on employment and health status. Liver Transpl Surg 1996;2:148-153.
5. Sirrs S, Yoshida E, Wong L, et al. Ortho-topic liver transplantation in a patient with carbamyl phosphate synthetase deficiency and cystic fibrosis. Paediatr Child Health 2003;8:497-498.
6. Yoshida EM. Selecting candidates for liver transplantation: A medical ethics perspective on the microallocation of a scarce and rationed resource. Can J Gas-troenterol 1998;12:209-215.
7. Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001;33:464-470.
8. Ostapowicz G, Fontana RJ, Schiodt FV, et al. Results of a prospective study of acute liver failure at 17 tertiary care cen-ters in the United States. Ann Intern Med 2002;137:947-954.
9. Watt KD, Burak K, Deschenes M, et al. Recurrent hepatitis C post-transplantation: Where are we now and where do we go from here? A report from the CanaCanadian transplant hepatology workshop. Can J Gastroenterol 2006;20:725-734.
10. Gane EJ, Portmann BC, Naoumov NV, et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996;334:815-820.
11. Watt KD, Lyden ER, McCashland TM. Poor survival after liver retransplantation: Is hepatitis C to blame? Liver Transpl 2003;9:1019-1024.
12. Rodriguez-Luna H, Khatib A, Sharma P, et al. Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon alpha2b and ribavirin: An open-label series. Transplantation 2004;77:190-194.
13. Davis GL, Nelson DR, Terrault N, et al. A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civa cir) in liver transplant recipients. Liver Transpl 2005;11:941-949.
14. Steinmuller T, Seehofer D, Rayes N, et al. Increasing applicability of liver transplan-tation for patients with hepatitis B-relat-ed liver disease. Hepatology 2002;35: 1528-1535.
15. Yoshida EM, Erb SR, Partovi N, et al. Liver transplantation for chronic hepatitis B infection with the use of combination lamivudine and low-dose hepatitis B immune globulin. Liver Transpl Surg 1999;5:520-525.
16. McGory RW, Ishitani MB, Oliveira WM, et al. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization. Transplantation 1996;61: 1358-1364.
17. Lo CM, Liu CL, Chan SC, et al. Failure of hepatitis B vaccination in patients receiv-ing lamivudine prophylaxis after liver transplantation for chronic hepatitis B. J Hepatol 2005;43:283-287.
18. McMaster P. Transplantation for alcoholic liver disease in an era of organ shortage. Lancet 2000;355(9202):424-425.
19. Bird GL, O'Grady JG, Harvey FA, et al. Liver transplantation in patients with alco-holic cirrhosis: Selection criteria and rates of survival and relapse. BMJ 1990;301: 15-17.
20. Gish RG, Lee AH, Keeffe EB, et al. Liver transplantation for patients with alco-holism and end-stage liver disease. Am J Gastroenterol 1993;88:1337-1342.
21. El-Serag HB, Davila JA, Petersen NJ, et al. The continuing increase in the inci-dence of hepatocellular carcinoma in the United States: An update. Ann Intern Med 2003;139:817-823.
22. Zou S, Tepper M, El Saadany S. Predic-tion of hepatitis C burden in Canada. Can J Gastroenterol 2000;14:575-580.
23. Figueras J, Ibanez L, Ramos E, et al. Selection criteria for liver transplantation in early-stage hepatocellular carcinoma with cirrhosis: Results of a multicenter study. Liver Transpl 2001;7:877-883.
24. Yao FY, Bass NM, Nikolai B, et al. Liver transplantation for hepatocellular carci-noma: Analysis of survival according to the intention-to-treat principle and dropout from the waiting list. Liver Transpl 2002;8:873-883.
25. Ratziu V, Samuel D, Sebagh M, et al. Long-term follow-up after liver transplantation for autoimmune hepatitis: Evidence of recurrence of primary disease. J Hepatol 1999;30:131-141.
26. Yoshida EM, Caron NR, Buczkowski AK, et al. Indications for liver transplantation in British Columbia's Aboriginal population: A 10-year retrospective analysis. Can J Gastroenterol 2000;14:775-779.
27. Neuberger J. Transplantation for autoim-mune hepatitis. Semin Liver Dis 2002; 22:379-386.
28. Liermann Garcia RF, Evangelista Garcia C, McMaster P, et al. Transplantation for primary biliary cirrhosis: Retrospective analysis of 400 patients in a single center. Hepatology 2001;33:22-27.
29. Wiesner RH, Porayko MK, Dickson ER, et al. Selection and timing of liver trans-plantation in primary biliary cirrhosis and primary sclerosing cholangitis. Hepatol-ogy 1992;16:1290-1299.
30. Neuberger JM, Gunson BK, Buckels JA, et al. Referral of patients with primary bil-iary cirrhosis for liver transplantation. Gut 1990;31:1069-1072.
31. Graziadei IW, Wiesner RH, Marotta PJ, et al. Long-term results of patients under-going liver transplantation for primary sclerosing cholangitis. Hepatology 1999; 30:1121-1127.
32. Kim WR, Therneau TM, Wiesner RH, et al. A revised natural history model for pri-mary sclerosing cholangitis. Mayo Clin Proc 2000;75:688-694.
33. Campsen J, Zimmerman MA, Trotter JF, et al. Clinically recurrent primary scleros-ing cholangitis following liver transplan-tation: A time course. Liver Transpl 2008; 14:181-185.
34. Bergquist A, Broome U. Hepatobiliary and extrahepatic malignancies in primary sclerosing cholangitis. Best Pract Res Clin Gastroenterol 2001;15:643-656.
35. Vera A, Gunson BK, Ussatoff V, et al. Colorectal cancer in patients with inflammatory bowel disease after liver transplan-tation for primary sclerosing cholangitis. Transplantation 2003;75:1983-1988.
36. Groth CG, Dubois RS, Corman J, et al. Metabolic effects of hepatic replacement in Wilson's disease. Transplant Proc 1973;5:829-833.
37. Yu L, Ioannou GN. Survival of liver trans-plant recipients with hemochromatosis in the United States. Gastroenterology 2007;133:489-495.
38. Vennarecci G, Gunson BK, Ismail T, et al. Transplantation for end stage liver disease related to alpha 1 antitrypsin. Trans-plantation 1996;61:1488-1495.
39. Alali J, Ramji A, Ho JK, et al. Liver transplant candidacy unsuitability: A review of the British Columbia experience. Can J Gastroenterol 2006;20:95-99.
40. Bouscarat F, Samuel D, Simon F, et al. An observational study of 11 French liver transplant recipients infected with human immunodeficiency virus type 1. Clin Infect Dis 1994;19:854-859.
41. Sherman KE, Rouster SD, Chung RT, et al. Hepatitis C Virus prevalence among patients infected with human immuno-deficiency virus: A cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis 2002;34:831-837.
42. Ragni MV, Belle SH, Im K, et al. Survival of human immunodeficiency virus-infect-ed liver transplant recipients. J Infect Dis 2003;188:1412-1420.
43. Brown RS, Jr., Russo MW, Lai M, et al. A survey of liver transplantation from living adult donors in the United States. N Engl J Med 2003;348:818-825.
44. Facciuto M, Heidt D, Guarrera J, et al. Retransplantation for late liver graft failure: Predictors of mortality. Liver Transpl 2000;6:174-179.